UNCY FY2024 EPS Raised by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Brookline Capital Management increased their FY2024 earnings per share estimates for Unicycive Therapeutics in a report released on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings of ($0.03) per share for the year, up from their prior forecast of ($0.08). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.15) EPS.

Several other analysts have also commented on the company. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Trading Up 2.7 %

Shares of UNCY stock opened at $0.46 on Monday. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The stock has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.54. The company has a market capitalization of $47.75 million, a P/E ratio of -0.47 and a beta of 2.29.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL grew its stake in Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after purchasing an additional 1,493,462 shares in the last quarter. Virtu Financial LLC bought a new position in Unicycive Therapeutics in the 1st quarter valued at about $36,000. Bleakley Financial Group LLC bought a new position in shares of Unicycive Therapeutics during the third quarter worth approximately $33,000. Great Point Partners LLC acquired a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $3,491,000. Finally, Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $807,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.